Advice
in the absence of a submission from the holder of the marketing authorisation
ketoconazole (Ketoconazole HRA®) 200 mg tablets are not recommended for use within NHS Scotland.
Indication under review: Treatment of endogenous Cushing’s syndrome in adults and adolescents above the age of 12 years.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice141KB (PDF)
Medicine details
- Medicine name:
- ketoconazole (Ketoconazole HRA)
- SMC ID:
- 1100/15
- Indication:
- Treatment of endogenous Cushing' s syndrome in adults and adolescents above the age of 12 years
- Pharmaceutical company
- HRA Pharma UK Ltd
- BNF chapter
- Endocrine system
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 07 September 2015